These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16819578)

  • 21. Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities.
    Ward RP; Anderson AS
    Postgrad Med; 2001 Mar; 109(3):36-8, 41-5. PubMed ID: 11265361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.
    Yoshida T; Tabony AM; Galvez S; Mitch WE; Higashi Y; Sukhanov S; Delafontaine P
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2322-32. PubMed ID: 23769949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autonomic effects of spironolactone and MR blockers in heart failure.
    Davies JI; Witham MD; Struthers AD
    Heart Fail Rev; 2005 Jan; 10(1):63-9. PubMed ID: 15947893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of aldosterone blockade in patients with heart failure.
    Pitt B
    Heart Fail Rev; 2005 Jan; 10(1):79-83. PubMed ID: 15947895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
    Fügedi K
    Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-blockers and spironolactone in heart failure.
    Kukin ML
    Curr Cardiol Rep; 2000 Mar; 2(2):87-9. PubMed ID: 10980877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure.
    Muñoz-Pacheco P; Ortega-Hernández A; Caro-Vadillo A; Casanueva-Eliceiry S; Aragoncillo P; Egido J; Fernández-Cruz A; Gómez-Garre D
    J Hypertens; 2013 Nov; 31(11):2309-18; discussion 2319. PubMed ID: 24077250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novelties in Therapy of Chronic Heart Failure.
    Doimo S; Pavan D
    Heart Fail Clin; 2021 Apr; 17(2):255-262. PubMed ID: 33673949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia.
    Martins T; Vitorino R; Moreira-Gonçalves D; Amado F; Duarte JA; Ferreira R
    Clin Biochem; 2014 Jan; 47(1-2):8-15. PubMed ID: 24184665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
    James R; Guillot E; Garelli-Paar C; Huxley J; Grassi V; Cobb M
    J Vet Cardiol; 2018 Feb; 20(1):1-12. PubMed ID: 29277469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Aldosterone antagonists for all patients with heart failure?].
    Bauersachs J
    MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
    [No Abstract]   [Full Text] [Related]  

  • 34. Aldosterone antagonism and myocardial infarction: from animals to man and back.
    Solomon SD; Pfeffer MA
    J Am Coll Cardiol; 2003 Nov; 42(9):1674-6. PubMed ID: 14607458
    [No Abstract]   [Full Text] [Related]  

  • 35. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
    Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference.
    von Haehling S; Stepney R; Anker SD
    Int J Cardiol; 2010 Oct; 144(3):347-9. PubMed ID: 20561693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How does cachexia influence survival in cancer, heart failure and other chronic diseases?
    Lainscak M; Podbregar M; Anker SD
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):299-305. PubMed ID: 18685379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Aldosterone blockade in heart failure. So much for so little].
    González-Juanatey JR; Mazón Ramos P
    Med Clin (Barc); 2002 Jun; 118(20):779-81. PubMed ID: 12049694
    [No Abstract]   [Full Text] [Related]  

  • 40. Pathophysiology of peripheral muscle wasting in cardiac cachexia.
    Filippatos GS; Anker SD; Kremastinos DT
    Curr Opin Clin Nutr Metab Care; 2005 May; 8(3):249-54. PubMed ID: 15809526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.